All data are based on the daily closing price as of October 8, 2026
s

Sysmex

6869.TSE
11.90 USD
-0.10
-0.83%

Overview

Last close
11.90 usd
Market cap
7.20B usd
52 week high
19.13 usd
52 week low
8.27 usd
Target price
13.41 usd

Valuation

P/E
33.3802
Forward P/E
27.933
Price/Sales
2.1779
Price/Book Value
2.3055
Enterprise Value
7.14B usd
EV/Revenue
2.2575
EV/EBITDA
11.3048

Key financials

Revenue TTM
3.32B usd
Gross Profit TTM
1.69B usd
EBITDA TTM
729.53M usd
Earnings per Share
0.36 usd
Dividend
0.23 usd
Total assets
4.59B usd
Net debt
60.84M usd

About

Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software. It offers hematology, a major test routinely included in blood tests; Flow Cytometry (FCM) analyzes cell properties by irradiating individual cells with a laser and measuring the intensity of light scattering and fluorescence; urinalysis test checks for the presence of glucose, proteins, and blood in urine; clinical chemistry; hemostasis; immunochemistry; cancer gene testing; and antimicrobial susceptibility testing. The company also provides Caresphere, an ICT solution, which integrates and analyzes real time various data managed through testing instruments and clinical testing information systems, and supports the efficient operation of clinical laboratories; and involved in the medical robotics business. It serves products and services to medical institutions, clinical laboratories, animal hospitals, and research institutes. The company was formerly known as TOA Medical Electronics Co., Ltd. and changed its name to Sysmex Corporation in October 1998. Sysmex Corporation was founded in 1968 and is headquartered in Kobe, Japan.
  • Symbol
    6869.TSE
  • Exchange
    TSE
  • Isin
    JP3351100007
  • Country
    Japan
  • Sector
    Healthcare
  • Industry
    Medical Devices
  • CEO
    Mr. Hisashi Ietsugu
  • Headquarter
    Kobe
  • Web site
    https://www.sysmex.co.jp
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top